首页> 外文OA文献 >NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

【2h】

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

机译：NpC1L1抑制剂依泽替米贝是非酒精性脂肪性肝病非肥胖患者的可靠治疗药物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kotoh Kazuhiro; Kato Masaki; Kohjima Motoyuki; Machida Kazuyuki; Enjoji Munechika; Matsunaga Kazuhisa; Nakashima Manabu; Nakamuta Makoto;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease [J] . Munechika Enjoji, Kazuyuki Machida, Motoyuki Kohjima, Lipids in Health Disease . 2010,第1期

机译：NPC1L1抑制剂依泽替米贝是非肥胖非酒精性脂肪肝患者的可靠治疗剂
2. The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. [J] . Park H, Hasegawa G, Shima T, Clinica chimica acta: International journal of clinical chemistry and applied molecular biology . 2010,第21a22期

机译：非酒精性脂肪肝患者血浆胆固醇酯的脂肪酸组成和估计的去饱和酶活性，以及长期依泽替米贝治疗对这些水平的影响。
3. The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. [J] . Park H, Hasegawa G, Shima T, Clinica chimica acta: International journal of clinical chemistry and applied molecular biology . 2010,第21a22期

机译：非酒精性脂肪肝患者血浆胆固醇酯的脂肪酸组成和估计的去饱和酶活性，以及长期依泽替米贝治疗对这些水平的影响。
4. A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records [C] . Pradyumna Byappanahalli Suresha, Yunlong Wang, Cao Xiao, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020

机译：使用电子医疗记录对非酒精性脂肪肝病患者的非酒精性脂肪性肝炎患者的深入学习方法
5. Relationships between hyperleptinemia, hyperinsulinemia, hypertriglyceridemia and elevations in markers of liver disease for nonalcoholic fatty liver disease in Hispanic children. [D] . Patel, Bhavin. 2003

机译：高脂蛋白血症，高胰岛素血症，高甘油三酯血症与西班牙裔儿童非酒精性脂肪肝疾病肝脏疾病标志物升高之间的关系。
6. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease [O] . Munechika Enjoji, Kazuyuki Machida, Motoyuki Kohjima, 2010

机译：NPC1L1抑制剂依泽替米贝是非肥胖非酒精性脂肪肝患者的可靠治疗剂
7. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease [O] . Munechika Enjoji, Kazuyuki Machida, Motoyuki Kohjima, 2010

机译：NPC1L1抑制剂依泽替米贝是非肥胖非酒精性脂肪肝患者的可靠治疗剂

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

著录项

引文网络

相似文献

相关主题

期刊订阅